n the process of cardiac remodeling after myocardial infarction (MI), infarct expansion occurs as an acute dilatation and thinning of the infarcted region, and is followed by ventricular dilatation and myocardial hypertrophy in the non-infarcted regions. This cardiac remodeling is associated with progressive systolic and diastolic dysfunction, and an increased incidence of congestive heart failure and sudden death. [1] [2] [3] [4] The changes in the myocardial tissue are related to structural rearrangement in the infarcted and non-infarcted regions, characterized by myocardial cell damage, hypertrophy and expression of extracellular matrix components. It is well known that the angiotensin blockade can prevent cardiac remodeling and has prolonged survival in both experimental models of MI and in patients after MI. 5-9 Beta-adrenergic blockers are also used in the treatment of MI and have been shown to reduce morbidity and mortality, presumably by preventing myocardial ischemia and arrhythmia. [10] [11] [12] However, the effects of -adrenergic blockers on left ventricular (LV) remodeling after MI are still unclear. Previous experimental studies have suggested that propranolol promotes LV dilation following MI, which would adversely affect LV function 13,14 and we have reported that 100 mg·kg -1 ·day -1 of atenolol facilitated LV remodeling after MI. 15 However, other -adrenergic block-
ers, which have a vasodilating action, do not have clear beneficial effects on ventricular remodeling after MI. Nipradilol (3,4-dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran) is a non-selectiveadrenergic blocker that has a vasodilating action partly mediated by a nitrate moiety of its chemical structure. 16, 17 Experimentally, nipradilol prevents the increase in heart weight, LV end-diastolic pressure (LVEDP) and LV enddiastolic volume index after MI, 18, 19 but it is still unclear whether nipradilol prevents the progressive systolic and diastolic dysfunction that accompanies the change in the non-infarcted myocardial tissue during cardiac remodeling after MI. To elucidate the effects of nipradilol on cardiac remodeling in a rat model of MI, LV geometry and cardiac function were assessed by Doppler echocardiography and the cardiac gene expression of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), which are markers of the hypertrophic response of cardiomyocytes, and collagen I and III, which are markers of fibrosis, in non-infarcted areas of the left and right ventricles were investigated by northern blot analysis.
Methods

Experimental Protocol
MI was produced, as described previously, 20 in male Wistar rats, weight 290-310 g (Clea Japan, Osaka, Japan). Briefly, the rats were anesthetized by injection of pentobarbital sodium (35 mg/kg ip) and a left thoracotomy was performed under volume-controlled mechanical ventilation (tidal volume, 3.0 ml; respiration rate, 60 cycles/min). A ligature of 6-0 prolene was placed around the proximal left anterior descending coronary artery. The same surgical procedures were also performed in sham-operated rats (n=8), except for the coronary artery ligation. Rats with MI surviving the operation for 24 h were randomly divided into untreated and nipradilol-treated groups. Ten mg·kg -1 ·day -1 of nipradilol was administered orally by gastric gavage once daily from 1 day after MI for 4 weeks (each group; n=8). 18, 19 The dose of nipradilol used in the present study did not affect the mean arterial pressure in the MI. 18 The rats in the untreated group were administered vehicle (5% gum arabic solution) in the same manner.
Doppler Echocardiography
We performed transthoracic echocardiography on each rat by modifying the procedure used in a previous study. 21 Rats were lightly anesthetized by an injection of ketamine hydrochloride (25-50 mg/kg ip) and xylazine (5-10 mg/kg). Echocardiograms were performed with an echocardiography system equipped with a 7.5-MHz phased-array transducer (SONOS 5500; Agilent Technologies, Andover, MA, USA). M-mode tracings were recorded through the anterior and posterior LV walls at a paper speed of 100 mm/s. We measured the area of the right ventricular (RV) cavity at the level of the papillary muscle of left ventricle. Moving the transducer toward the cardiac apex and angling it anteriorly enabled the acquisition of an apical 4-chamber view. The high-frequency neonatal transducers used in this study allowed us to obtain good-quality transthoracic images of the beating rat heart. Pulsed-wave Doppler spectra of mitral inflow were recorded from the apical 4-chamber view, with the sample volume placed near the tips of the mitral leaflets maximal and the flow pattern laminar. The sample volume was set at the smallest size available. All Doppler spectra were recorded on paper at 100 mm/s and analyzed off-line as previously described. The mean of at least 3 consecutive cardiac cycles was used.
Hemodynamic Studies
One day after the echocardiogram, hemodynamic studies were performed under the treatment with nipradilol or vehicle. The rats were anesthetized by injection of pentobarbital sodium (35 mg/kg body weight ip). Aortic and LV pressures were recorded by inserting a polyethylene tube catheter into the right carotid artery and advancing it into the aorta and left ventricle. Central venous pressure (CVP) was measured by cannulating the right external jugular vein with a PE-50 tube catheter, which was advanced to the region of the thoracic vena cava. Aortic and central venous pressures were recorded as the mean values determined by electronic averaging, and LVEDP was obtained by averaging the values for 10 beats. Heart rate was determined from the tracing of aortic pressure. Following these measurements, MI rats and sham-operated rats were decapitated, and the heart quickly removed. The myocardial infarct size was measured as previously described. 22 Rats with an infarction of less than 20% in size were excluded. Following determination of the infarct size, the heart was divided into the LV and RV, and non-infarcted LV myocardium around the infarcted region was removed. After weighing, the RV and non-infarcted LV were rapidly frozen in liquid nitrogen and stored at -80°C until use.
RNA Preparation and Northern Blot Hybridization
All procedures were performed, as previously described in detail. 23 In brief, the total RNA was isolated from each heart by the guanidium thiocyanate-phenol-chloroform method. Twenty milligrams of total RNA were electrophoresed on a 1% agarose gel and transferred to a nylon membrane, and then hybridization was carried out with a ( 32 P)-dCTP-labeled cDNA probe for ANP, BNP, collagen types I and III, and rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The densities of an individual mRNA band were measured by a bioimaging analyzer (BAS-2000, Fuji Photo Film Co, Tokyo, Japan). For all RNA samples, the density of an individual mRNA band was divided by that of the GAPDH mRNA band, to correct for differences in RNA loading and/or transfer.
Statistics
All results are expressed as mean ± SEM. Statistical significance was determined using ANOVA and Duncan's multiple range tests. Differences were considered significant at p<0.05.
Results
Effect of Nipradilol on Ventricular Weight and Hemodynamics
As shown in Fig 1 and Table 1 , MI significantly increased LVEDP (sham: 3±1 mmHg; MI: 13±2 mmHg, p<0.01) and CVP (sham: 2±0 mmHg; MI: 6±1 mmHg; p<0.01), and the LV weight/body weight (sham: 2.04±0.04 g/kg; MI: 2.22± 0.03 g/kg; p<0.01) and RV weight/body weight ratios (sham: 0.47±0.02 g/kg; MI: 0.79±0.02 g/kg; p<0.01) were also increased in the MI rats. Nipradilol significantly prevented the increase in the weight of the left and right ventricles (1.94±0.07 and 0.62±0.03 g/kg, p<0.01) and reduced LVEDP and CVP to 9±2 mmHg (p<0.05) and 4±1 mmHg (p<0.01), respectively, compared with untreated MI rats.
Echocardiographic Assessment of LV and RV Geometry and Function
Fig 2 shows representative 2-dimensional echocardiograms from each group in the parasternal short-axis view. The LV end-diastolic dimension (LVDd) was significantly increased in MI rats (sham: 6.7±0.3 mm; MI: 10.3±0.2 mm; p<0.01) ( Table 2) . As evidenced by the decreased fractional shortening (FS), MI rats showed significant systolic dysfunction (sham: 34±0.6%; MI: 17.2±0.3%; p<0.01). Nipradilol prevented both the increase in LVDd (9.0±0.2 mm, p<0.01 to MI) and the decrease in FS (23.5±0.3%, p<0.01 to MI). Moreover, the RV systolic and diastolic areas were increased significantly in the MI rats and nipradilol significantly prevented the RV dilatation.
Examples of pulsed-wave Doppler recordings of mitral inflow from the 3 groups are shown in Fig 3. Representing the diastolic dysfunction, the peak early diastolic filling wave (E wave) velocity was increased and the atrial filling wave (A wave) velocity was decreased in the MI rats, resulting in a marked increase in the ratio of E to A wave velocity (sham: 2.0±0.2; MI: 8.5±0.3; p<0.01). The deceleration of the E wave of the MI rats became rapid (sham: 9.0±0.3 m/s 2 ; MI: 22.3±2.6 m/s 2 ; p<0.01). Nipradilol significantly prevented the worsening of diastolic function after MI. Fig 4) The expression of ANP and BNP mRNA increased by 5.1-and 3.5-fold, respectively (p<0.01), in the septal region, and by 5.3-and 2.8-fold, respectively (p<0.01), in the RV. 
Gene Expression of ANP, BNP and Collagens Following MI and Effects of Nipradilol (Table 3,
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Nipradilol significantly prevented the increased gene expression in these regions. Furthermore, the expression of myocardial collagen I and III mRNA was increased in MI rats, and nipradilol significantly prevented these increases in both regions.
Discussion
We have shown that after MI in rats, nipradilol can prevent the increase in the LV and RV weights and in the LVEDP, CVP and LVDd, the decrease in FS and the worsening of the transmitral flow pattern, and can inhibit LV dilatation with modulation of mRNA expression of ANP, BNP and collagen I and III. These results suggest that nipradilol improves the hemodynamics and the systolic and diastolic dysfunction that occur after MI and that it may be a useful therapeutic agent for LV remodeling.
We previously reported in a study investigating the effects of atenolol on the MI-induced LV remodeling in rats, that 100 mg · kg -1 · day -1 of atenolol facilitated LV remodeling after MI, 15 and a recent study also demonstrated a slight increase in LV weight in metoprolol-treated MI rats. 24 Those findings suggest that treatment by -blocking action alone may not have preventive effects on LV remodeling after MI and therefore, the beneficial effects of nipradilol on LV remodeling are not the result solely of its -blocking action. The mechanisms by which nipradilol reduces LV remodeling after MI was unclear from the present study, but we propose that it may result from a combination of -blocking and vasodilator activity. The effects of -blockers on LV remodeling after MI are not yet fully elucidated, but probably result from the improvement in the hemodynamic function of the LV caused by a combination of heart rate reduction and inhibition of the detrimental neurohormonal activation present in cardiac dysfunction. 25 In addition, nipradilol has a nitrate moiety of its chemical structure, which may contribute to preventing LV remodeling because Hirai et al reported that in a canine model of MI the long-term administration of nitrates reduced LV remodeling and they suggested that this was a result of decreased preload and afterload and/or increased collateral blood flow. 26 The effect of nipradilol on preload and afterload would therefore seem to be an important mechanism of its ability to reduce LV remodeling.
On the other hand, Raya et al have demonstrated that hydralazine, which reduces afterload, did not alter LV remodeling. 27 Decreasing afterload is supposedly an important mechanism for reducing LV remodeling, but reducing the afterload stimulates sympathetic tone and increases heart rate by vasomotor reflex, which may have an adverse effect on the prevention of LV remodeling. It may be the combination of vasodilator action and -adrenergic blocker that enables nipradilol to preventing LV remodeling. ANP and BNP are upregulated in the ventricle with increased work load, which probably contributes to the increased level of circulating peptide that in turn tends to decrease preload and afterload. 28 Increased production of ANP and BNP would normalize the working conditions of the cardiac pump, but these changes become ineffective during the transition from hypertrophy to failure. In addition, the levels of ANP and BNP mRNA increase in the myocardium of the failing heart, and we reported that fetal genes ( -myosin heavy chain, -skeletal actin, ANP) are expressed in the non-infarcted myocardium. 20 Nipradilol not only prevented cardiac hypertrophy but also inhibited the gene expression of ANP, BNP and collagen I and III, which supports our hypothesis that the effect of theblocker, NO and/or the improvement of hemodynamics may be involved in the shift of myocytes to the fetal phenotype after MI as well as in ventricular hypertrophy.
There are several potential mechanisms of the significant Autoradiograms of northern blot analysis of mRNA expression of ANP, BNP, collagen I and III and GAPDH in the LV non-infarcted region (septum) at 4 weeks after MI. mRNA expression of ANP, BNP and collagen I and III were increased in the MI rats compared with sham-operated rats. These parameters in the MI rats treated with nipradilol were significantly lower than in the untreated MI rats. improvement in diastolic dysfunction observed after nipradilol treatment. As mentioned earlier, we considered the potential effects of alterations in preload: reducing the LV filling pressure explains in large part the improvement in the LV filling pattern. Central blood volume and venous tone are important components of preload and both of these may be improved by nipradilol. Moreover, changes in the passive elastic properties of the myocardium would alter the LV filling characteristics in diastole 29 ; that is, interstitial fibrosis is believed to increase cardiac stiffness and impair diastolic dysfunction. 29, 30 In the present study, increased levels of the mRNA of collagen type I and III were inhibited by nipradilol and so inhibition of interstitial collagen accumulation may prevent the diastolic dysfunction after MI. Furthermore, reducing myocyte hypertrophy may decrease LV chamber stiffness. Because abnormalities of diastole are common in the hypertrophic hearts, preventing hypertrophy of the non-infarcted myocardium may contribute to improved LV filling. In addition, nipradilol inhibited the increase in RV weight and dilatation, and the expression of fetal and collagen genes. These RV parameters appeared to be a useful markers of RV remodeling in the present model 31 and nipradilol prevented the RV remodeling.
Conclusion
Nipradilol treatment for 4 weeks after MI attenuated LV remodeling and improved cardiac function. It is proposed that it is the combination of its -blocking effects and preload reduction that gives nipradilol its beneficial effects on LV remodeling after MI, but further work is needed to demonstrate pathophysiological and clinical evidence of the beneficial preventive effects of nipradilol.
